Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Tuberculosis Treatment in Patients with Comorbidities

  • Kang, Young Ae (Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine)
  • Received : 2014.03.24
  • Accepted : 2014.04.07
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Tuberculosis is a significant infectious problem in elderly patients with comorbidities in Korea. The age-associated diseases such as malignancy and diabetes mellitus may increase the risk of tuberculosis in this population. The medication treatments of tuberculosis in patients with comorbidities can cause adverse reactions to antituberculosis drugs and inadequate treatment responses. Thus, clinicians must carefully monitor the toxicity of antituberculosis therapy and the efficacy of treatment in patients with comorbidities.

Keywords

References

  1. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis 2013;74:104-10. https://doi.org/10.4046/trd.2013.74.3.104
  2. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2011.
  3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. https://doi.org/10.1164/rccm.167.4.603
  4. World Health Organization. Treatment of tuberculosis guideline. 4th ed. Geneva: World Health Organization; 2010.
  5. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-11. https://doi.org/10.1378/chest.127.4.1304
  6. Park WB, Kim W, Lee KL, Yim JJ, Kim M, Jung YJ, et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010;61:323-9. https://doi.org/10.1016/j.jinf.2010.07.009
  7. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, et al. Guidelines for the pre-vention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70. https://doi.org/10.1136/thx.2010.144295
  8. Subramanian AK, Morris MI; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:68-76. https://doi.org/10.1111/ajt.12100
  9. Kim DK, Lee SW, Yoo CG, Kim YW, Han SK, Shim YS, et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 2005;128:2218-22. https://doi.org/10.1378/chest.128.4.2218

Cited by

  1. Treatment of Drug Susceptible Pulmonary Tuberculosis vol.78, pp.3, 2014, https://doi.org/10.4046/trd.2015.78.3.161
  2. Metformin in tuberculosis: beyond control of hyperglycemia vol.47, pp.5, 2014, https://doi.org/10.1007/s15010-019-01322-5